BI 765179 + ezabenlimab

BI 765179 + ezabenlimab is an investigational combination therapy under clinical development for advanced solid tumors. BI 765179 is a novel monoclonal antibody targeting the immune system, particularly via immune modulation, and this is its first trial in humans. Ezabenlimab (also known as BI 754091) is a programmed cell death protein 1 (PD-1) inhibitor monoclonal antibody. Together, these drugs aim to enhance anticancer immune responses by acting on different immune pathways. The combination is being studied primarily in patients whose cancers have not responded to standard therapies. Both drugs are administered intravenously, typically every three weeks, and are being evaluated for safety, tolerability, and anticancer activity. This immunotherapy approach is intended to help the body’s own immune system recognize and destroy cancer cells[1][2][3][4][6].